UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Switzerland Not Applicable (State or other jurisdiction of incorporation or organization) Baarerstrasse 14 6300 Zug, Switzerland Not Applicable (I.R.S. Employer Identification No.) (Address of principal executive offices) (Zip Code) For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE ...

CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results —Clinical trials ongoing for next generation CAR T product candidates, CTX112™ and CTX131™ targeting CD19 and CD70 respectively, across multiple indications — —Clinical trial ongoing for CTX211™, an allogeneic, hypoimmune, gene-edited, stem cell derived product candidate for the treatment of Type 1 Diabetes (T1D) — ZUG, Switzerland and BOSTON, Mass., May 8, 2024 – CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceut ...

While a weakening economy and a subsequent dip in the stock market are unfortunate, they are inevitabilities. Even booming segments like the biotech sector are not immune to the general trend of recessions that Western economies experienced over the last 40 years or so. These downturns, however, provide opportunities for investors to buy stocks at lower prices. The case is the same for which biotech stocks to buy in a down market.Knowing when to buy a stock during market turmoil can be the difference betwee ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this company have returned -18.5% over the past month versus the Zacks S&P 500 composite's -4.1% change. The Zacks Medical - Biomedical and Genetics industry, to which CRISPR Therapeutics belongs, has lost 10.7% over this period. Now the key question is: Where could the stock be ...

janiecbros As investors search for disruptive companies within the biotech sector, it is helpful to consider disruptive technologies that necessarily precede them. Specifically, the revolutionary CRISPR/Cas9 gene-editing platform has recently made headlines with FDA approval of a revolutionary drug named Casgevy. This therapy, pioneered by CRISPR Therapeutics (NASDAQ: CRSP), amazingly recognizes the correct segment of DNA to edit by using a piece of RNA as a guide. The Cas9 protein then cuts the patient's D ...

CRISPR Therapeutics AG (CRSP) closed the latest trading day at $53.91, indicating a +0.34% change from the previous session's end. The stock's performance was behind the S&P 500's daily gain of 1.02%. Meanwhile, the Dow gained 0.4%, and the Nasdaq, a tech-heavy index, added 2.03%.Heading into today, shares of the company had lost 21.17% over the past month, lagging the Medical sector's loss of 5.2% and the S&P 500's loss of 3.15% in that time.Analysts and investors alike will be keeping a close eye on the p ...

CRISPR Therapeutics AG (CRSP) closed at $55.02 in the latest trading session, marking a -0.05% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.87%. Elsewhere, the Dow gained 0.67%, while the tech-heavy Nasdaq added 1.11%.Coming into today, shares of the company had lost 23.13% in the past month. In that same time, the Medical sector lost 6.67%, while the S&P 500 lost 3.97%.Market participants will be closely following the financial results of CRISPR Therapeutics AG ...

Crispr Therapeutics AG (NASDAQ:CRSP) is 2.8% lower at $56.35 this afternoon, continuing a pullback from a Feb. 22, more than two-year high of $91.10. Over the last month, CRSP has erased 20.8% and now sports a 9.6% year-to-date deficit.For those looking to buy in on the dip, however, the recent pullback puts Crispr Therapeutics stock within one standard deviation of its 320-day moving average, a trendline with historically bullish implications. According to Schaeffer's Senior Quantitative Analyst Rocky Whit ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this company have returned -19.5%, compared to the Zacks S&P 500 composite's -1.1% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has lost 8.3%. The key question now is: What could be the ...

There's no guarantee these stocks will double by 2030, but their growth prospects look great.Does a 100% return in less than seven years sound pretty good? Most investors would probably say so. But which stocks are good candidates to achieve such a gain?Three Motley Fool contributors think they've found magnificent stocks that could double or more by 2030. Here's why they picked CRISPR Therapeutics (CRSP -3.56%), Eli Lilly (LLY -1.05%), and Viking Therapeutics (VKTX -3.17%).A ton of upside for CRISPR Therap ...